Scholarlink

Background <p>Human cathelicidin LL-37 is one of the best studied antimicrobial peptides. It is usually expressed at high concentrations by various white blood cells. Owing to its wide distribution in human body, LL-37 is considered to play an important role in the innate immune defense against bacterial and viral infections. Previous studies have demonstrated that LL-37 effectively disrupts bacterial membranes and promotes wound healing, which further underscored its therapeutic relevance.</p> Methods <p>This study evaluated the antimicrobial activity and minimum inhibitory concentration (MIC) of recombinantly produced human LL-37. Antimicrobial testing was performed on forty-three clinical bacterial strains, isolated from patients with various bacterial infections. Following this testing, we evaluated the MIC concentrations of recombinantly produced LL-37 for each bacterial strain, which may provide an indication of the concentrations that could be required for potential therapeutic efficacy.</p> Results <p>All tested clinical isolates were susceptible to LL-37 under the experimental conditions, confirming its broad-spectrum antimicrobial activity. This finding is consistent with previous reports, indicating that natural resistance to LL-37 is uncommon among bacterial pathogens.</p> Conclusion <p>The MIC concentrations obtained for our recombinant LL-37 were comparable to those reported for chemically synthesized and commercially available LL-37. Our findings also demonstrate that recombinant LL-37 exhibits consistent antimicrobial activity across diverse clinical isolates, supporting its potential as a promising candidate for future therapeutic development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Potential of Human Recombinant Cathelicidin LL-37 in the Treatment of Infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Lea Lukáčová,
  • Adriána Dusíková,
  • Lucia Krahulcová,
  • Miroslav Dolník,
  • Ján Krahulec

摘要

Background

Human cathelicidin LL-37 is one of the best studied antimicrobial peptides. It is usually expressed at high concentrations by various white blood cells. Owing to its wide distribution in human body, LL-37 is considered to play an important role in the innate immune defense against bacterial and viral infections. Previous studies have demonstrated that LL-37 effectively disrupts bacterial membranes and promotes wound healing, which further underscored its therapeutic relevance.

Methods

This study evaluated the antimicrobial activity and minimum inhibitory concentration (MIC) of recombinantly produced human LL-37. Antimicrobial testing was performed on forty-three clinical bacterial strains, isolated from patients with various bacterial infections. Following this testing, we evaluated the MIC concentrations of recombinantly produced LL-37 for each bacterial strain, which may provide an indication of the concentrations that could be required for potential therapeutic efficacy.

Results

All tested clinical isolates were susceptible to LL-37 under the experimental conditions, confirming its broad-spectrum antimicrobial activity. This finding is consistent with previous reports, indicating that natural resistance to LL-37 is uncommon among bacterial pathogens.

Conclusion

The MIC concentrations obtained for our recombinant LL-37 were comparable to those reported for chemically synthesized and commercially available LL-37. Our findings also demonstrate that recombinant LL-37 exhibits consistent antimicrobial activity across diverse clinical isolates, supporting its potential as a promising candidate for future therapeutic development.